These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 26261600)

  • 1. SATB2 is a sensitive marker for lower gastrointestinal well-differentiated neuroendocrine tumors.
    Li Z; Yuan J; Wei L; Zhou L; Mei K; Yue J; Gao H; Zhang M; Jia L; Kang Q; Huang X; Cao D
    Int J Clin Exp Pathol; 2015; 8(6):7072-82. PubMed ID: 26261600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin.
    Yang C; Sun L; Zhang L; Zhou L; Zhao M; Peng Y; Niu D; Li Z; Huang X; Kang Q; Jia L; Lai J; Cao D
    Am J Surg Pathol; 2018 Feb; 42(2):160-171. PubMed ID: 28914716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
    Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
    Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours.
    Hoskoppal D; Epstein JI; Gown AM; Arnold Egloff SA; Gordetsky JB; Shi CJ; Giannico GA
    Histopathology; 2020 Mar; 76(4):550-559. PubMed ID: 31595536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
    Bellizzi AM
    Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
    Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
    Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SATB2 Is Superior to CDX2 in Distinguishing Signet Ring Cell Carcinoma of the Upper Gastrointestinal Tract and Lower Gastrointestinal Tract.
    Ma C; Lowenthal BM; Pai RK
    Am J Surg Pathol; 2018 Dec; 42(12):1715-1722. PubMed ID: 30212392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma: A Concise Review of Benefits and Pitfalls.
    Berg KB; Schaeffer DF
    Arch Pathol Lab Med; 2017 Oct; 141(10):1428-1433. PubMed ID: 28968158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of SATB2 Expression in Colorectal Carcinoma Is Associated With DNA Mismatch Repair Protein Deficiency and BRAF Mutation.
    Ma C; Olevian DC; Lowenthal BM; Jayachandran P; Kozak MM; Chang DT; Pai RK
    Am J Surg Pathol; 2018 Oct; 42(10):1409-1417. PubMed ID: 30001238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
    Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
    J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinomas can be Special AT-rich sequence-binding protein 2 positive: an important diagnostic pitfall.
    Lee W; Li X; Chandan VS
    Hum Pathol; 2020 Nov; 105():47-52. PubMed ID: 32946879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.
    Meagher NS; Wang L; Rambau PF; Intermaggio MP; Huntsman DG; Wilkens LR; El-Bahrawy MA; Ness RB; Odunsi K; Steed H; Herpel E; Anglesio MS; Zhang B; Lambie N; Swerdlow AJ; Lubiński J; Vierkant RA; Goode EL; Menon U; Toloczko-Grabarek A; Oszurek O; Bilic S; Talhouk A; García-Closas M; Wang Q; Tan A; Farrell R; Kennedy CJ; Jimenez-Linan M; Sundfeldt K; Etter JL; Menkiszak J; Goodman MT; Klonowski P; Leung Y; Winham SJ; Moysich KB; Behrens S; Kluz T; Edwards RP; Gronwald J; Modugno F; Hernandez BY; Chow C; Kelemen LE; Keeney GL; Carney ME; Natanzon Y; Robertson G; Sharma R; Gayther SA; Alsop J; Luk H; Karpinskyj C; Campbell I; Sinn P; Gentry-Maharaj A; Coulson P; Chang-Claude J; Shah M; Widschwendter M; Tang K; Schoemaker MJ; Koziak JM; Cook LS; Brenton JD; Daley F; Kristjansdottir B; Mateoiu C; Larson MC; Harnett PR; Jung A; deFazio A; Gorringe KL; Pharoah PDP; Minoo P; Stewart C; Bathe OF; Gui X; Cohen P; Ramus SJ; Köbel M
    Mod Pathol; 2019 Dec; 32(12):1834-1846. PubMed ID: 31239549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic.
    Perez Montiel D; Arispe Angulo K; Cantú-de León D; Bornstein Quevedo L; Chanona Vilchis J; Herrera Montalvo L
    Ann Diagn Pathol; 2015 Aug; 19(4):249-52. PubMed ID: 26059401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SATB2 is expressed in neuroendocrine carcinoma of the uterine cervix.
    Inzani F; Angelico G; Santoro A; Travaglino A; Insabato L; Raffone A; Arciuolo D; Scaglione G; D'Alessandris N; Valente M; Carlino A; Rindi G; Zannoni GF
    Virchows Arch; 2022 Apr; 480(4):873-877. PubMed ID: 35091815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of SATB2 immunostaining in the distinction between small intestinal and colorectal adenocarcinomas.
    Kim CJ; Baruch-Oren T; Lin F; Fan XS; Yang XJ; Wang HL
    J Clin Pathol; 2016 Dec; 69(12):1046-1050. PubMed ID: 27169755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SATB2 Expression in Human Tumors: A Tissue Microarray Study on More Than 15 000 Tumors.
    Dum D; Kromm D; Lennartz M; De Wispelaere N; Büscheck F; Luebke AM; Burandt E; Menz A; Kluth M; Hube-Magg C; Hinsch A; Höflmayer D; Weidemann S; Fraune C; Möller K; Lebok P; Sauter G; Simon R; Uhlig R; Wilczak W; Minner S; Krech R; Bernreuther C; Marx A; Steurer S; Jacobsen F; Clauditz T; Krech T
    Arch Pathol Lab Med; 2023 Apr; 147(4):451-464. PubMed ID: 35917493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of SATB2, ISL1, and TTF1 to differentiate rectal from other gastrointestinal and lung well-differentiated neuroendocrine tumors.
    Zhao LH; Chen C; Mao CY; Xiao H; Fu P; Xiao HL; Wang G
    Pathol Res Pract; 2019 Jul; 215(7):152448. PubMed ID: 31133441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases.
    Sangoi AR; Kshirsagar M; Horvai AE; Roma AA
    Int J Gynecol Pathol; 2017 Mar; 36(2):140-145. PubMed ID: 27294605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SATB2 is a novel marker of osteoblastic differentiation and colorectal adenocarcinoma.
    Ordóñez NG
    Adv Anat Pathol; 2014 Jan; 21(1):63-7. PubMed ID: 24316906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemistry in the Diagnosis of Mucinous Neoplasms Involving the Ovary: The Added Value of SATB2 and Biomarker Discovery Through Protein Expression Database Mining.
    Strickland S; Wasserman JK; Giassi A; Djordjevic B; Parra-Herran C
    Int J Gynecol Pathol; 2016 May; 35(3):191-208. PubMed ID: 26535987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.